Dr. Shih, Hsiu-Ming 施修明 博士


Dr. Shih, Hsiu-Ming
施修明 博士

Research Fellow

  • Ph.D. Department of Biochemistry, Molecular Biology, and Biophysics, University of Minnesota

  • 2789-9060 (Lab) (Room No: N605)
  • 2652-3520 (Office)
  • 2782-7654 (Fax)
  • Protein-protein Interaction & Modification
  • Cancer Cell Signaling
  • Transcriptional Control


Wrestling with SUMO in Cancer


SUMO modification is emerging as an important post-translational control of cellular events. My lab primarily focused on the molecular mechanisms as to how protein sumoylation is regulated and what consequence of a protein is sumoylated in cancer giving that sumoylation levels are elevated in several types of human cancer. We have demonstrated several other modifications such as phosphorylation and acetylation could control protein sumoylation. Since SUMO pathway has been considered as a non-oncogene addiction in cancer, targeting SUMO machinery and/or sumoylated substrates could not only understand the underlying mechanism of sumoylation associated with cancer but also increase the repertoire of druggable targets against cancer. Studies are undergoing to dissect the functional significances of cancer-associated sumoylated factors as well as to develop therapeutic agents in targeting SUMO conjugation and binding in cancer.




類泛素(SUMO) 修飾調控了許多細胞運作途徑。本實驗室研究主要聚焦於蛋白質 sumoylation 是如何被調節以及類泛素化蛋白質在癌症中的功能進行分子機制的探討,尤其是 sumoylation在幾種類型的癌症中普遍升高。另外,我們也證明了其他幾種蛋白質後轉譯修飾,如磷酸化和乙醯化,可以控制蛋白質 sumoylation。由於 SUMO 訊息途徑被認為是癌症中需要依靠的非癌基因成癮(non-oncogene addiction),因此靶向 SUMO 機制和/或 sumoylated 蛋白質不僅可以了解與癌症相關的 sumoylation 的分子機轉,亦可增加抗癌藥物靶點的選擇。目前研究以剖析癌症相關的 SUMO 化因子的意義以及開發針對癌症中的 SUMO 結合和接合的治療劑。


Reciprocal regulation of Daxx and PIK3CA promotes colorectal cancer cell growth
Cellular and Molecular Life Sciences, Jun 19, 2022